呼吸道合胞病毒疫苗的研究进展

Progress of respiratory syncytial virus vaccine

呼吸道合胞病毒感染是引起婴儿、儿童、免疫力低下的病人、老年人等高危人群患病和死亡的一个重要因素，在这样高疾病风险下，还没有一种安全有效的疫苗上市。因此，呼吸道合胞病毒疫苗已被WHO列为全球最优先发展的疫苗之一。该文对呼吸道合胞病毒的结构、感染机制、病毒的F和G两种重要蛋白等生物学性状、主动和被动免疫疫苗的发展以及存在的一些问题等方面进行综述。

Respiratory syncytial virus（RSV） infection is an important factor for causing illness and death in global high-risk groups, such as infants, children, and immunocompromised patients, and the elderly. As a high risk factor, there is still no safe and effective vaccine. Therefore, RSV vaccine has been regarded as one of the vaccines that needs to be developed globally by the World Health Organization（WHO）. The important biological characteristics such as the structure of RSV,infection mechanism, and two important glycoproteins： fusion and attachment, active and passive immunization vaccine development, as well as some of the aspects were reviewed.